Latest news with #StephenWilley
Business Insider
15-07-2025
- Business
- Business Insider
Compass Therapeutics (CMPX) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Stephen Willey reiterated a Buy rating on Compass Therapeutics today and set a price target of $11.00. The company's shares opened today at $2.66. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Willey covers the Healthcare sector, focusing on stocks such as Incyte, Bicara Therapeutics Inc., and Exelixis. According to TipRanks, Willey has an average return of 2.0% and a 40.34% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Compass Therapeutics with a $13.20 average price target, which is a 396.24% upside from current levels. In a report released on July 1, Raymond James also initiated coverage with a Buy rating on the stock with a $9.00 price target. CMPX market cap is currently $373.4M and has a P/E ratio of -6.74. Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMPX in relation to earlier this year. Most recently, in May 2025, Thomas Schuetz, the CEO of CMPX bought 10,000.00 shares for a total of $21,100.00.
Business Insider
25-06-2025
- Business
- Business Insider
Stifel Nicolaus Initiates a Buy Rating on Gyre Therapeutics (GYRE)
Gyre Therapeutics (GYRE – Research Report) received a Buy rating and a $28.00 price target from Stifel Nicolaus analyst Stephen Willey today. The company's shares closed today at $7.61. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Willey is a 3-star analyst with an average return of 1.5% and a 39.19% success rate. Willey covers the Healthcare sector, focusing on stocks such as Bicara Therapeutics Inc., Exelixis, and Incyte. Gyre Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $21.00, implying a 175.95% upside from current levels. In a report released on June 18, LifeSci Capital also initiated coverage with a Buy rating on the stock with a $22.00 price target. Based on Gyre Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $22.06 million and a net profit of $5.54 million. In comparison, last year the company earned a revenue of $27.17 million and had a net profit of $7.53 million
Business Insider
04-06-2025
- Business
- Business Insider
Stifel Nicolaus Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
In a report released on June 2, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), with a price target of $48.00. The company's shares closed yesterday at $11.01. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Willey covers the Healthcare sector, focusing on stocks such as Bicara Therapeutics Inc., Exelixis, and Abeona Therapeutics. According to TipRanks, Willey has an average return of 0.5% and a 37.45% success rate on recommended stocks. In addition to Stifel Nicolaus, Bicara Therapeutics Inc. also received a Buy from H.C. Wainwright's Robert Burns in a report issued yesterday. However, on May 23, Wells Fargo upgraded Bicara Therapeutics Inc. (NASDAQ: BCAX) to a Hold.
